Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood cancer anemia drug study halted early

NCT ID NCT04582539

First seen Oct 31, 2025 · Last updated Jun 14, 2026 · Updated 29 times

Summary

This study tested a new drug called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. It was open to those who needed blood transfusions or had anemia symptoms. The study aimed to find a safe dose and check for side effects, but it was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    Florence, 50134, Italy

  • Barbara Ann Karmanos Cancer Hospital

    Detroit, Michigan, 48201, United States

  • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu

    Nantes, 44093, France

  • Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo

    Pavia, 27100, Italy

  • Florida Cancer Specialists

    Sarasota, Florida, 34232, United States

  • Hospices Civils de Lyon Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Institut Gustave Roussy

    Villejuif, 94800, France

  • Irccs Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi

    Bologna, 40138, Italy

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Stanford Cancer Center

    Palo Alto, California, 94304, United States

  • Tulane Comprehensive Cancer Center

    New Orleans, Louisiana, 70112, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

Conditions

The condition(s) this trial relates to.

anemia Myelodysplastic Syndromes plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.